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Abstract
Background—Anthrax vaccine adsorbed (AVA) administered intramuscularly (IM) results in 
fewer adverse events (AEs) than subcutaneous (SQ) administration. Women experience more AEs 
than men. Antibody response, female hormones, race, and body mass index (BMI) may contribute 
to increased frequency of reported injection site AEs.
Methods—We analyzed data from the CDC AVA human clinical trial. This double blind, 
randomized, placebo controlled trial enrolled 1563 participants and followed them through 8 
injections (AVA or placebo) over a period of 42 months. For the trial’s vaccinated cohort (n = 
1267), we used multivariable logistic regression to model the effects of study group (SQ or IM), 
sex, race, study site, BMI, age, and post-vaccination serum anti-PA IgG on occurrence of AEs of 
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any severity grade. Also, in a women-only subset (n = 227), we assessed effect of pre-vaccination 
serum progesterone level and menstrual phase on AEs.
Results—Participants who received SQ injections had significantly higher proportions of itching, 
redness, swelling, tenderness and warmth compared to the IM study group after adjusting for other 
risk factors. The proportions of redness, swelling, tenderness and warmth were all significantly 
lower in blacks vs. non-black participants. We found arm motion limitation, itching, pain, swelling 
and tenderness were more likely to occur in participants with the highest anti-PA IgG 
concentrations. In the SQ study group, redness and swelling were more common for obese 
participants compared to participants who were not overweight. Females had significantly higher 
proportions of all AEs compared to males. Menstrual phase was not associated with any AEs.
Conclusions—Female and non-black participants had a higher proportion of AVA associated 
AEs and higher anti-PA IgG concentrations. Antibody responses to other vaccines may also vary 
by sex and race. Further studies may provide better understanding for higher proportions of AEs in 
women and non-black participants.
Keywords
Anthrax vaccine adsorbed; Anthrax vaccines/adverse events; Sex factors; Race; Body mass index; 
Immunological response
1. Introduction
Anthrax vaccine absorbed (AVA, Biothrax, Emergent Bio-Solutions, Lansing, Michigan), is 
the only anthrax vaccine licensed in the United States. Originally licensed in 1970, the 
principal immunogen is protective antigen (PA) and the adjuvant is aluminum hydroxide. 
The original approved AVA regimen consisted of 0.5 mL SQ injections at 0, 2 and 4 weeks 
and 6, 12, and 18 months with annual boosters thereafter [1]. Since the introduction of the 
Department of Defense’s (DoD) mandatory anthrax vaccination program in 1998 [2], service 
personnel and others have raised concerns that subsequently have been addressed in various 
published studies, including those related to high rates of injection site adverse events, (AEs) 
particularly in women [3–8]; potential reproductive toxicity [9–11]; physical disability [12–
15]; and nonspecific longer term symptoms such as Gulf War and chronic fatigue syndromes 
[16–19]. In 1999, the US Congress directed the Centers for Disease Control and Prevention 
(CDC) to evaluate the safety and efficacy of AVA and in particular an apparent sex 
difference in the occurrence of AEs. A pivotal component of the CDC’s Anthrax Vaccine 
Safety and Efficacy Research Program was the AVA human clinical trial to evaluate route 
change (SQ to IM) and dose reduction (reduced priming schedule of 0, 4 weeks and 6 
months and a biannual/triannual booster) [20]. Participants (n = 1563) received a total of 8 
doses of vaccine or saline placebo during 42 months. Following the trial’s interim analysis, 
the FDA revised the licensed schedule to specify IM administration and the exclusion of the 
two week priming dose [21]; and the Advisory Committee for Immunization Practices 
(ACIP) revised its recommendations for vaccine use [22,23].
Details of the clinical trial were previously published [24,25]. In summary, changing from 
SQ to IM administration reduced the frequency of AEs in men and women and substantially 
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diminished absolute differences in occurrence of AEs between men and women. We 
conducted this study to investigate potential risk factors for AEs and the role of the 
menstrual cycle with regard to injection site reactogenicity in women.
2. Methods
The CDC AVA human clinical trial was a randomized, double-blind, placebo-controlled, 
Phase 4 study conducted from 2002 to 2005 with participants enrolled and followed at 5 
major U.S. vaccine research centers: Baylor College of Medicine, Houston, TX; Emory 
University School of Medicine, Atlanta, GA; Mayo Clinic, Rochester, MN; University of 
Alabama at Birmingham; and the Walter Reed Army Institute of Research, Silver Springs, 
MD. Eligibility requirements included being 18–61 years of age, healthy, having two intact 
upper arms, indicating a willingness to participate, having no history of anthrax infection or 
immunization against anthrax and if female, not being pregnant and not planning to be 
pregnant during the study period.
At each study site, participants were randomly assigned to one of six study groups based on 
receiving either AVA or saline placebo, route of injection (SQ vs. IM), and full/reduced AVA 
schedule (full = 0.5 mL doses at 0, 2, and 4 weeks, and 6, 12, 18, 30 and 42 months vs. 
reduced = substituting one or more injections with placebo doses). The SQ study group, 
group 8-SQ, received AVA as originally licensed. Group 8-IM received 8 doses of AVA IM. 
Groups 7-IM, 5-IM, and 4-IM also received AVA IM with saline placebo doses at one or 
more time points. The sixth group received 8 IM or SQ saline placebo doses and did not 
receive any AVA (Table 1). We combined participants in the 8-IM, 7-IM, 5-IM, and 4-IM 
groups into one IM study group. All placebo doses were excluded from analysis.
At enrollment, each participant self-identified his/her age, race, and sex; and clinical staff 
collected their height and weight measurements. Female trial participants were separately 
consented to have serum progesterone measured. Each participant’s age at baseline was 
categorized as <30, 30–39, 40–49, and 50+ years of age. Race was categorized as black, 
white, and other and we grouped the white and other categories as non-black for analysis. 
Body mass index (BMI) was computed using height and weight at enrollment and each 
follow up, and categorized using CDC categories: underweight (<18.5), normal (18.5–24.9), 
overweight (25–29.9), and obese (≥30) [26]. For analysis, the following three BMI 
categories were used: not overweight (BMI < 25), overweight (25–29.9), and obese (BMI ≥ 
30).
Serum progesterone levels were measured for women in the SQ study group and for a subset 
of women in the IM study group. Since menstrual phases can more easily be determined in 
the absence of pharmacologically altered hormone levels, we excluded data from any doses 
when a woman was on pharmacological birth control. There were 227 pre-menopausal, non-
pregnant females included in the women-only subset analysis. Pre-menopausal was defined 
as having self-reported regular menses during the 12-month period prior to enrollment.
Solicited and unsolicited AEs were actively monitored. However, for our study, we limited 
our analysis to only the solicited injection site AEs: arm motion limitation, bruising, itching, 
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pain, redness, swelling, tenderness, and warmth recorded in a diary for up to 5 days. In 
addition to the diary, participants received a circular ruler to measure the widest diameter, in 
millimeters, of injection-site bruising, redness, or swelling. Participants were also screened 
for AEs during scheduled in-clinic examinations that occurred at 15 to 60 min after each 
injection and two days after each injection. Mild, moderate, or severe AEs were collapsed to 
create a binary variable indicating the presence or absence of an AE of any severity grade 
after a given dose.
Blood was drawn from study participants to measure pre and post-vaccination immune 
response. Total serum anti-protective antigen IgG antibody (anti-PA IgG) was measured 
using a quantitative enzyme-linked immunosorbent assay (ELISA) as described previously 
[27]. Concentrations of anti-PA IgG from post-vaccination blood samples, collected four 
weeks after the third to eighth injections, were calculated and categorized in quartiles. For 
the women-only subset analysis, serum progesterone levels were measured using the pre-
vaccination blood draw. Serum progesterone concentration was assayed using the ADVIA 
Centaur® Progesterone Assay, which is a competitive immunoassay using direct 
chemiluminescent technologies [28]. The values of serum progesterone concentration 
provided by the testing laboratory were 0.2–1.4 and 3.3–26.0 ng/mL for follicular phase and 
luteal phase, respectively. We used the pre-vaccination progesterone concentration to assign 
a menstrual phase variable with three categories, follicular, luteal, or ovulation.
2.1. Statistical analysis
Our analysis included data from injections 3 to 8. One of our study objectives was to test for 
associations between post-injection anti-PA IgG concentrations and AEs. Doses 1 and 2 
were excluded from our analysis because the anti-PA IgG concentrations, collected 4 weeks 
after injection, were at the lower limit of detection for about half of the study population 
after dose 1 and were not measured after dose 2 (occurred only 2 weeks after dose 1).
We compared the mean pre-injection progesterone concentrations and the mean post-
injection anti-PA IgG concentrations, from injections 3 to 8, between study groups using the 
Wilcoxon rank sum test. We tested for differences in the distribution of risk factors for AEs 
reported in the patient diary between study groups using chi-square tests for categorical 
variables.
We modeled the log odds of experiencing an AE, adjusted for BMI category, race, post-
injection anti-PA IgG level, sex, study site, age category, and study group using logistic 
regression and generalized estimating equations with an exchangeable covariance structure 
to account for repeated measurements within a participant. We tested all possible two way 
interactions and excluded risk factors and interactions from the model if they did not have a 
significant type 3 Wald test statistic. Relative risks (RR) were then estimated using the 
marginal method [29]. To calculate confidence intervals for the RR, we created 1000 
bootstrapped data sets from random draws on individual injection data. Separate logistic 
models were run for each AE.
We performed several sensitivity analyses. We compared the results from the multivariable 
analysis using data from injections 3 to 8 to the results using data from all doses. We also 
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substituted pre-injection IgG concentrations and the change in IgG between the pre-injection 
and post-injection measurements for post-injection IgG concentration in the multivariable 
model and compared the results. To assess the accuracy of the diary data we also modeled 
the risk of AEs as assessed by study nurses during the scheduled in-clinic exams.
3. Results
3.1. Vaccinated cohort—Comparison of participants in SQ and IM study groups
There were 252 participants from the SQ study group and 1015 participants from the IM 
study group included in our analysis (Table 1). There was no significant difference between 
the two study groups in race, sex, BMI, or study site (Table 2). However, the age distribution 
of participants was significantly different between the study groups (p = 0.02). The average 
post-injection anti-PA IgG concentration from injections 3 to 8 was higher in the IM study 
group (mean = 261.01 (SQ) vs. 325.07 (IM), p = 0.04).
3.2. Vaccinated cohort—Multivariable models
Age group was not significantly associated with any AE and thus was not included in our 
multivariable models. Sex and study group were significantly associated with AEs as 
expected. Females had significantly higher rates for all AEs (Table 4). Participants who 
received SQ AVA had significantly higher rates of itching, redness, swelling, tenderness, and 
warmth than IM study group participants after adjusting for other risk factors.
Arm motion limitation, redness, swelling, tenderness, and warmth were all significantly less 
frequent in blacks vs. non-black participants. The risk of bruising was higher in blacks in the 
SQ study group (RR = 1.82, 95% CI = 1.42, 2.33). There was no difference in the risk of 
bruising between blacks and non-blacks in the IM study group.
Participants in the obese BMI category had a significantly lower rate of arm motion 
limitation (RR = 0.79, 95% CI = 0.71, 0.91) and a higher rate of warmth (RR = 1.16, 95% 
CI = 1.04, 1.29) than participants who were not overweight. We modeled the interaction 
between BMI and study group for five AEs: bruising, itching, redness, swelling, and 
tenderness. For these AEs, obesity was significantly associated with bruising and itching 
only in the SQ study group (Table 4). Obese participants were significantly more likely to 
experience redness, swelling, and tenderness in the SQ study group but significantly less 
likely to experience the same AE in the IM study group compared to participants who were 
not overweight.
The quartiles of anti-PA IgG concentration were <95, 95–204.1, 204.1–396.2 and ≥396.2 
μg/mL (i.e., quartiles 1–4, respectively). Participants with post-vaccination anti-PA IgG 
concentrations in the top two quartiles were more likely to experience itching, pain, 
tenderness, and warmth than those with anti-PA IgG concentrations in the lowest quartile. 
We modeled an interaction between study group and anti-PA IgG level for redness and 
swelling. Participants in the IM study group with anti-PA IgG concentrations in the top three 
quartiles were more likely to experience redness and swelling than those with anti-PA IgG 
concentrations in the lowest quartile.
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3.3. Women only subset—Comparison of participants in SQ and IM study groups
There were 80 participants from the SQ study group and 147 participants from the IM study 
group included in the women-only analysis (Table 1). There was no significant difference 
between the proportions of participants in the two study groups by race, age category, or 
study site (Table 2). The proportion of participants in the three BMI categories did differ 
between the two study groups (p = 0.04). The average post-injection anti-PA IgG 
concentration from injections 3 to 8 was higher in the IM study group (262.29 (SQ) vs. 
322.52 (IM), p = 0.01). The mean progesterone level from AVA injection 3 until the end of 
the study was borderline significantly higher in the IM study group (3.75 (SQ) vs. 4.22 (IM), 
p = 0.06).
As we found in the analysis with all participants, the proportion of women experiencing 
bruising, itching, redness, swelling and warmth differed significantly across the two study 
groups with higher proportions of AEs in the SQ study group (p < 0.01 for all 5 AEs). 
However, the proportions of women with arm motion limitation, pain, and tenderness were 
similar across study groups (Table 3).
3.4. Women only subset—Multivariable models
Relative risks and 95% confidence intervals for the repeated measures analysis are shown in 
Table 5. As before, age was not included in the multivariable models. After adjusting for 
other risk factors, menstrual phase was not significantly associated with any AE. Black 
women were significantly less likely than non-black women to experience redness, swelling, 
tenderness, and warmth. Interactions between study group and BMI remained significant in 
the models for redness, swelling, and warmth. Obese women who received SQ AVA were 
significantly more likely to experience redness, swelling, and warmth compared to women 
who were not overweight (Table 5). The quartiles of anti-PA IgG concentration in the 
women-only subset analysis were <122.4, 122.4–215.4, 215.4–390.5 and ≥390.5. Women 
with higher anti-PA IgG concentrations were more likely to experience arm motion 
limitation, itching, pain, swelling, and tenderness. Women in the IM group were 
significantly more likely to experience warmth if their anti-PA IgG level was in the highest 
quartile.
4. Discussion
Our results for several AEs were consistent in our overall study population and in the 
women-only subgroup. Redness, swelling, tenderness, and warmth were less likely for 
blacks compared to non-blacks in all analyses. In all analyses, arm motion limitation, 
itching, pain, and tenderness were more likely to occur in participants with the highest anti-
PA IgG concentrations. Redness increased with increasing anti-PA IgG only in the IM group 
of all analyses. All analyses indicated that redness and swelling were more likely in the 
obese SQ study group participants. SQ injection and elevated post-injection anti-PA IgG 
concentration were independent risk factors for several AEs. In addition, although 
participants in the SQ study group had higher proportions of most AEs compared with the 
IM study group, they had lower anti-PA IgG concentrations after injections 3 to 8.
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A potential limitation of our study was the use of the diary data. This may have introduced 
confounding if there were differences in the likelihood of participants noting and/or 
reporting AE and this was associated with sex, racial category, or BMI category. Based on 
our comparison of diary data to in-clinic data, we do not believe that the subjective nature of 
diary data biased our results. We found similar results when comparing the risk of AEs that 
were measured in-clinic to the risk of AEs recorded in the diary data (data not shown).
A 2002 study by Zhang et al. evaluated BMI, serum progesterone and anti-PA IgG on AEs 
following AVA in women in the CDC Anthrax Vaccination Program (AVP) [30]. The women 
in that study received SQ AVA according to the original 6-dose subcutaneous schedule, also 
pre-vaccination blood samples for serum anti-PA IgG level and serum progesterone were 
tested and data on solicited AEs were obtained using a self-completed four day diary. These 
investigators found an elevated risk for arm soreness in obese women, an association 
between decreased pre-vaccination serum progesterone level and arm swelling, and an 
association between increased pre-vaccination anti-PA IgG and itching on the arm. There 
was also an association in obese women between increased pre-vaccination anti-PA IgG and 
redness, swelling, warmth, and presence of a “lump or knot” at the injection site. In 
comparison, our analysis found a significant association between increased post-vaccination 
anti-PA IgG and itching (RR = 1.71, 95% CI = 1.38, 2.15). We found that, in the SQ study 
group, obese women had a higher risk of redness, swelling, and warmth compared to women 
who were not overweight. Lump or knot was not an AE included in our study. Soreness was 
not included in our study but we used tenderness as a comparison. Although we did not find 
associations between tenderness and obesity in women, we did find increased tenderness in 
obese participants in the SQ study group of the combined analysis (RR = 1.08, 95% CI = 
1.01, 1.17). We did not find associations between serum progesterone concentration and arm 
swelling.
Our study included 80 women who received SQ AVA compared with 128 such women 
studied by Zhang et al. We did see higher rates of arm swelling in women with decreased 
serum progesterone levels but this association was not statistically significant (RR = 1.05, 
95% CI = 0.95, 1.19). The small sample of women in the SQ study group might be another 
limitation of our study. Moreover, our analysis only included data from doses 3 to 8. We 
performed a sensitivity analysis (results not shown) including doses 1 to 8. When all doses 
were included in the model, our results were similar for all risk factors except serum anti-PA 
IgG concentration. The risk of pain for participants with anti-PA IgG concentrations in the 
highest quartile was slightly lower than the risk in the lowest quartile but the association 
between pain and anti-PA IgG was not significant. The associations between anti-PA IgG 
and other risk factors were either more significant or unchanged.
Our repeated measures analysis included post-vaccination anti-PA IgG as a risk factor. We 
performed sensitivity analyses including pre-vaccination anti-PA IgG instead of post-
vaccination anti-PA IgG in the multivariable model. For 7 of the 8 AEs we found weaker 
association between pre-vaccination anti-PA IgG and AEs than the associations between 
post-vaccination anti-PA IgG and AEs. However, participants with higher pre-vaccination 
anti-PA IgG had less pain than participants with lower concentrations (results not shown). 
An additional sensitivity analysis replaced post-vaccination anti-PA IgG with the difference 
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between pre- and post-vaccination as a risk factor in the multivariable analysis. Our results 
were similar whether we included post vaccination serum anti-PA IgG or the difference 
between pre- and post-vaccination serum anti-PA IgG as a risk factor for AEs (results not 
shown).
Differences in anti-PA IgG concentrations (i.e., lower anti-PA IgG) may explain the lower 
rate of AEs in black participants. The trial’s main analysis found that four weeks after the 
third injection anti-PA IgG concentrations for white participants were significantly higher 
than those of black participants [25]. We compared serum anti-PA IgG concentrations 
between black and non-black participants and found that the mean post injection anti-PA 
IgG concentration from injections 3 to 8 for black participants was lower than the mean 
concentration in non-blacks (224.2 vs. 235.2, p < 0.01). The mean pre-injection serum anti-
PA IgG level was also significantly lower in black vs. non-black participants (24.7 vs. 34.4, 
p < 0.01). In a phase 3 trial of two yellow fever vaccines, whites had higher antibody 
responses than blacks and Hispanics [31]. In addition, a study of acellular and whole cell 
pertussis vaccines among infants found a difference but in the opposite direction. Black 
infants had post-immunization geometric mean titers for every antigen in these vaccines 
which were twice as high as for white infants. Black infants also had more pain after 
receiving either pertussis vaccine [32].
Sex-specific differences in innate, humoral and cell-mediated immune responses to 
vaccination have been reported [33–35]. In addition, sex differences in the frequency and 
severity of adverse events (fever, pain, inflammation) following immunization have been 
noted for several vaccines including AVA [6,8], influenza [36,37], and measles mumps and 
rubella (MMR) [38,39]. In the pregnant woman, coincident with marked hormonal changes, 
there is a shift toward an anti-inflammatory phenotype which also likely influences cell-
mediated and humoral responses to vaccines [35]. Although precise biological mechanisms 
underlying the sex-specific responses to vaccines are unknown, genetic and hormonal factors 
are considered important [35]. Sex hormones have also been associated with a higher 
susceptibility to autoimmune diseases in women compared with men [40–42]. We 
hypothesize that hormonal phase may impact the occurrence of AEs in women. Estrogen has 
been shown to enhance the secretion of IgG [43]. As serum progesterone levels fluctuate 
more widely than serum estrogen during a woman’s menstrual cycle, we estimated 
menstrual phase based on serum progesterone levels. Because estrogen levels are highest 
during the follicular phase of the menstrual cycle [44], we hypothesized that we would see 
more AEs in women whose progesterone levels indicated that they were in the follicular 
phase, but we did not find this association.
In conclusion, we found female and non-black participants had higher anti-PA IgG 
concentrations and a higher incidence of AVA associated injection site AEs. In future 
analyses, we propose to study a possible effect of sex on AEs after placebo saline injections. 
Further studies of sex and racial differences in the occurrence of AEs with AVA and other 
vaccines should be considered.
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Table 1
Number of participants in vaccinated cohort and women-only subset by AVA trial study group.
Group Vaccinated cohort Women only subset
Total Includeda Female Includeda,b
8-SQ AVA 259 252 134 80
8-IM AVA 262 256 135 71
7-IM AVA 256 250 132 76
5-IM AVA 258 249 0 0
4-IM AVA 268 260 0 0
0-SQ Placebo 127 0 64 0
0-IM Placebo 133 0 68 0
Total 1563 1267 533 227
a
Doses 3–8.
b
Post-menopausal, surgically sterile, and women on pharmacologic birth control were excluded.
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